GAMIDA CELL said FDA has granted Breakthrough Therapy Designation to the company’s lead product candidate, NiCord, in development as a novel graft modality for bone marrow transplantation in patients with high risk hematological malignancies. The international, multi-center phase III registration study of NiCord is planned to begin before the end of the year, the company...
Readers of The Cancer Letter and listeners of The Cancer Letter Podcast are familiar with the impact of President Donald Trump’s first nine months in office on the field of oncology. Now, the threats posed to oncology are being brought to the attention of a general audience—Jonathan Mahler, staff writer for The New York Times Magazine, wrote an in-depth article about how the Trump administration’s actions have brought chaos, uncertainty, and damage to the oncology research community.
